Weight loss is associated with rapid striatal dopaminergic degeneration in Parkinson's disease

Kyoungjune Pak; Hae Kyung Shin; Eun Joo Kim; Jae Hyeok Lee; Chul Hyoung Lyoo; Jongsang Son; Myung Jun Lee

doi:10.1016/j.parkreldis.2018.02.044

Weight loss is associated with rapid striatal dopaminergic degeneration in Parkinson's disease

Kyoungjune Pak, Hae Kyung Shin, Eun Joo Kim, Jae Hyeok Lee, Chul Hyoung Lyoo, Jongsang Son, Myung Jun Lee

Department of Neurology

Research output: Contribution to journal › Article › peer-review

16 Citations (Scopus)

Abstract

Introduction: Weight loss in Parkinson's disease (PD) is associated with poorer clinical outcomes and rapid disease progression. However, it is unclear whether a longitudinal association between weight loss and striatal dopaminergic degeneration exists. Methods: Using data from 171 PD patients in the Parkinson's Progression Markers Initiative (PPMI) cohort, we investigated longitudinal associations of change in body mass index (BMI) with striatal dopaminergic activity on ¹²³ I-N-3-fluoropropyl-2-beta-carboxymethoxy-3beta-(4-iodophenyl) nortropane ( ¹²³ I-FP-CIT) single positron emission computed tomography (SPECT). We defined BMI loss as a reduction in BMI value > 5% of baseline, and categorized the PD patients into 2 subgroups (patients with and without BMI loss). Linear mixed model (LMM) analysis was employed to compare the progression of striatal dopaminergic degeneration. Results: In LMM analyses, BMI values in PD patients were not correlated with clinical severities of parkinsonian motor deficits, cognitive impairment and depressive mood. However, BMI values were positively associated with changes in striatal ¹²³ I-FP-CIT binding over 24 months (caudate nucleus, estimate = 9.37 × 10 ⁻³ , p = 0.009; putamen, estimate = 7.04 × 10 ⁻³ , p = 0.031). Patients with BMI loss exhibited greater deterioration of striatal dopaminergic activity than those without (caudate nucleus, estimate = 3.35 × 10 ⁻³ , p = 0.008; putamen, estimate = 2.34 × 10 ⁻³ , p = 0.025). Conclusion: Our findings suggest a potential association between striatal dopaminergic activity with body weight or impairment in energy homeostasis. Body weight and its change may be a clinical biomarker reflecting striatal dopaminergic dysfunction in PD.

Original language	English
Pages (from-to)	67-72
Number of pages	6
Journal	Parkinsonism and Related Disorders
Volume	51
DOIs	https://doi.org/10.1016/j.parkreldis.2018.02.044
Publication status	Published - 2018 Jun

Bibliographical note

Funding Information:
Parkinson's Progression Markers Initiative (PPMI) - a public-private partnership - is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including AbbVie, Avid, Biogen, Bristol-Myers Squibb, Covance, GE Healthcare, Genentech, GlaxoSmithKline, Lundbeck, Eli Lilly, Merck, MesoScaleDiscovery, Pfizer, Piramal, Roche, Sanofi Genzyme, Servier, TEVA, and UCB.

Funding Information:
Parkinson's Progression Markers Initiative (PPMI) - a public-private partnership - is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including AbbVie , Avid , Biogen , Bristol-Myers Squibb , Covance , GE Healthcare , Genentech , GlaxoSmithKline , Lundbeck , Eli Lilly , Merck , MesoScaleDiscovery , Pfizer , Piramal , Roche , Sanofi Genzyme , Servier , TEVA , and UCB .

Publisher Copyright:
© 2018 Elsevier Ltd

All Science Journal Classification (ASJC) codes

Neurology
Geriatrics and Gerontology
Clinical Neurology

Access to Document

10.1016/j.parkreldis.2018.02.044

Cite this

@article{74521bfcc1164fc380fdd0f6b5a9d58d,

title = "Weight loss is associated with rapid striatal dopaminergic degeneration in Parkinson's disease",

abstract = " Introduction: Weight loss in Parkinson's disease (PD) is associated with poorer clinical outcomes and rapid disease progression. However, it is unclear whether a longitudinal association between weight loss and striatal dopaminergic degeneration exists. Methods: Using data from 171 PD patients in the Parkinson's Progression Markers Initiative (PPMI) cohort, we investigated longitudinal associations of change in body mass index (BMI) with striatal dopaminergic activity on 123 I-N-3-fluoropropyl-2-beta-carboxymethoxy-3beta-(4-iodophenyl) nortropane ( 123 I-FP-CIT) single positron emission computed tomography (SPECT). We defined BMI loss as a reduction in BMI value > 5% of baseline, and categorized the PD patients into 2 subgroups (patients with and without BMI loss). Linear mixed model (LMM) analysis was employed to compare the progression of striatal dopaminergic degeneration. Results: In LMM analyses, BMI values in PD patients were not correlated with clinical severities of parkinsonian motor deficits, cognitive impairment and depressive mood. However, BMI values were positively associated with changes in striatal 123 I-FP-CIT binding over 24 months (caudate nucleus, estimate = 9.37 × 10 −3 , p = 0.009; putamen, estimate = 7.04 × 10 −3 , p = 0.031). Patients with BMI loss exhibited greater deterioration of striatal dopaminergic activity than those without (caudate nucleus, estimate = 3.35 × 10 −3 , p = 0.008; putamen, estimate = 2.34 × 10 −3 , p = 0.025). Conclusion: Our findings suggest a potential association between striatal dopaminergic activity with body weight or impairment in energy homeostasis. Body weight and its change may be a clinical biomarker reflecting striatal dopaminergic dysfunction in PD.",

author = "Kyoungjune Pak and Shin, {Hae Kyung} and Kim, {Eun Joo} and Lee, {Jae Hyeok} and Lyoo, {Chul Hyoung} and Jongsang Son and Lee, {Myung Jun}",

note = "Funding Information: Parkinson's Progression Markers Initiative (PPMI) - a public-private partnership - is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including AbbVie, Avid, Biogen, Bristol-Myers Squibb, Covance, GE Healthcare, Genentech, GlaxoSmithKline, Lundbeck, Eli Lilly, Merck, MesoScaleDiscovery, Pfizer, Piramal, Roche, Sanofi Genzyme, Servier, TEVA, and UCB. Funding Information: Parkinson's Progression Markers Initiative (PPMI) - a public-private partnership - is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including AbbVie , Avid , Biogen , Bristol-Myers Squibb , Covance , GE Healthcare , Genentech , GlaxoSmithKline , Lundbeck , Eli Lilly , Merck , MesoScaleDiscovery , Pfizer , Piramal , Roche , Sanofi Genzyme , Servier , TEVA , and UCB . Publisher Copyright: {\textcopyright} 2018 Elsevier Ltd",

year = "2018",

month = jun,

doi = "10.1016/j.parkreldis.2018.02.044",

language = "English",

volume = "51",

pages = "67--72",

journal = "Parkinsonism and Related Disorders",

issn = "1353-8020",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Weight loss is associated with rapid striatal dopaminergic degeneration in Parkinson's disease

AU - Pak, Kyoungjune

AU - Shin, Hae Kyung

AU - Kim, Eun Joo

AU - Lee, Jae Hyeok

AU - Lyoo, Chul Hyoung

AU - Son, Jongsang

AU - Lee, Myung Jun

N1 - Funding Information: Parkinson's Progression Markers Initiative (PPMI) - a public-private partnership - is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including AbbVie, Avid, Biogen, Bristol-Myers Squibb, Covance, GE Healthcare, Genentech, GlaxoSmithKline, Lundbeck, Eli Lilly, Merck, MesoScaleDiscovery, Pfizer, Piramal, Roche, Sanofi Genzyme, Servier, TEVA, and UCB. Funding Information: Parkinson's Progression Markers Initiative (PPMI) - a public-private partnership - is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including AbbVie , Avid , Biogen , Bristol-Myers Squibb , Covance , GE Healthcare , Genentech , GlaxoSmithKline , Lundbeck , Eli Lilly , Merck , MesoScaleDiscovery , Pfizer , Piramal , Roche , Sanofi Genzyme , Servier , TEVA , and UCB . Publisher Copyright: © 2018 Elsevier Ltd

PY - 2018/6

Y1 - 2018/6

N2 - Introduction: Weight loss in Parkinson's disease (PD) is associated with poorer clinical outcomes and rapid disease progression. However, it is unclear whether a longitudinal association between weight loss and striatal dopaminergic degeneration exists. Methods: Using data from 171 PD patients in the Parkinson's Progression Markers Initiative (PPMI) cohort, we investigated longitudinal associations of change in body mass index (BMI) with striatal dopaminergic activity on 123 I-N-3-fluoropropyl-2-beta-carboxymethoxy-3beta-(4-iodophenyl) nortropane ( 123 I-FP-CIT) single positron emission computed tomography (SPECT). We defined BMI loss as a reduction in BMI value > 5% of baseline, and categorized the PD patients into 2 subgroups (patients with and without BMI loss). Linear mixed model (LMM) analysis was employed to compare the progression of striatal dopaminergic degeneration. Results: In LMM analyses, BMI values in PD patients were not correlated with clinical severities of parkinsonian motor deficits, cognitive impairment and depressive mood. However, BMI values were positively associated with changes in striatal 123 I-FP-CIT binding over 24 months (caudate nucleus, estimate = 9.37 × 10 −3 , p = 0.009; putamen, estimate = 7.04 × 10 −3 , p = 0.031). Patients with BMI loss exhibited greater deterioration of striatal dopaminergic activity than those without (caudate nucleus, estimate = 3.35 × 10 −3 , p = 0.008; putamen, estimate = 2.34 × 10 −3 , p = 0.025). Conclusion: Our findings suggest a potential association between striatal dopaminergic activity with body weight or impairment in energy homeostasis. Body weight and its change may be a clinical biomarker reflecting striatal dopaminergic dysfunction in PD.

AB - Introduction: Weight loss in Parkinson's disease (PD) is associated with poorer clinical outcomes and rapid disease progression. However, it is unclear whether a longitudinal association between weight loss and striatal dopaminergic degeneration exists. Methods: Using data from 171 PD patients in the Parkinson's Progression Markers Initiative (PPMI) cohort, we investigated longitudinal associations of change in body mass index (BMI) with striatal dopaminergic activity on 123 I-N-3-fluoropropyl-2-beta-carboxymethoxy-3beta-(4-iodophenyl) nortropane ( 123 I-FP-CIT) single positron emission computed tomography (SPECT). We defined BMI loss as a reduction in BMI value > 5% of baseline, and categorized the PD patients into 2 subgroups (patients with and without BMI loss). Linear mixed model (LMM) analysis was employed to compare the progression of striatal dopaminergic degeneration. Results: In LMM analyses, BMI values in PD patients were not correlated with clinical severities of parkinsonian motor deficits, cognitive impairment and depressive mood. However, BMI values were positively associated with changes in striatal 123 I-FP-CIT binding over 24 months (caudate nucleus, estimate = 9.37 × 10 −3 , p = 0.009; putamen, estimate = 7.04 × 10 −3 , p = 0.031). Patients with BMI loss exhibited greater deterioration of striatal dopaminergic activity than those without (caudate nucleus, estimate = 3.35 × 10 −3 , p = 0.008; putamen, estimate = 2.34 × 10 −3 , p = 0.025). Conclusion: Our findings suggest a potential association between striatal dopaminergic activity with body weight or impairment in energy homeostasis. Body weight and its change may be a clinical biomarker reflecting striatal dopaminergic dysfunction in PD.

UR - http://www.scopus.com/inward/record.url?scp=85042701333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042701333&partnerID=8YFLogxK

U2 - 10.1016/j.parkreldis.2018.02.044

DO - 10.1016/j.parkreldis.2018.02.044

M3 - Article

C2 - 29510907

AN - SCOPUS:85042701333

SN - 1353-8020

VL - 51

SP - 67

EP - 72

JO - Parkinsonism and Related Disorders

JF - Parkinsonism and Related Disorders

ER -

Weight loss is associated with rapid striatal dopaminergic degeneration in Parkinson's disease

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this